Insights: Mergers & Acquisitions

Mergers & Acquisitions

BioCryst Pharmaceuticals/Astria Therapeutics

The companies are set to file HSR by November 12. We anticipate that the FTC will clear the deal without a second request, but there is some risk of antitrust attention. BioCryst and Astria both possess drugs indicated for hereditary angioedema (HAE) prophylaxis. BioCryst markets and supplies Orladeyo, an FDA-approved oral drug, while Astria is...

Mergers & Acquisitions

Novo Nordisk/Akero Therapeutics

The companies are set to file HSR by November 7. We believe the proposed merger is likely to avoid a second request. Novo's Wegovy (FDA-approved) and Akero's efruxifermin (Phase III) have the same indication –MASH with moderate-to-advanced liver fibrosis (F2-F3). Wegovy is also only one of two FDA-approved drugs indicated for MASH with...

Mergers & Acquisitions

The companies are due to file HSR on October 28. The MA contains a provision that if the filing deadline falls on a date that the Premerger Notification Office (PNO) is not accepting filings, the HSR deadline will be extended to the business day after the PNO begins accepting filings again. While the PNO remains open during the government...

Mergers & Acquisitions

The transaction received a second request from the FTC on September 17. There is substantial risk this deal could be challenged by the FTC. According to industry participants (who are not involved in the deal) 365 Retail (365) and Cantaloupe are the largest players in three unattended retail market segments: micro-markets, smart markets, and...

Mergers & Acquisitions

Compass/Anywhere

Based on research to date, we expect Compass/Anywhere will receive a second request from the DOJ. Feedback from industry participants (who are not involved in the deal) as well as industry reports indicate that the combined company will have a dominant share of the luxury home brokerage services market at both a national and local level. We...

Mergers & Acquisitions

The EC will soon decide whether to issue a formal statement of objections (SO) against the deal. An SO typically issues on or around the 40th business day of the EC’s review, which would be October 10th in this case. The M&A publication Dealreporter reported today that the case team reviewing the transaction has found no basis for an SO and has...